Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers - Trial NCT06398925
Access comprehensive clinical trial information for NCT06398925 through Pure Global AI's free database. This Phase 1 trial is sponsored by Oxford Cannabinoid Technologies Holdings PLC and is currently Completed. The study focuses on Healthy. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Oxford Cannabinoid Technologies Holdings PLC
Timeline & Enrollment
Phase 1
Jul 26, 2023
Sep 25, 2023
Primary Outcome
Number of Participants with Treatment Emergent Adverse Events during the study assessed as mild, moderate or severe
Summary
A study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of
 OCT461201. The study included a screening period, a single dose of study treatment or placebo
 and a follow up period.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06398925
Non-Device Trial